Abstract
Purpose: Clinical trials provide evidence that dose-dense chemotherapy (ddC) is more efficacious than standard chemotherapy schedules in the treatment of early breast cancer (EBC). The impact on toxicity and healthcare utilisation remains uncertain in real-world populations. The aim of this retrospective adjusted cohort comparison was to measure the impact following adoption of ddC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
